Seeking Ways to Accurately Monitor Glucose Levels Without Disrupting Users’ Daily Life
The product development team of a leading healthcare company was tasked with finding non-invasive continuous glucose monitoring (CGM) technologies to improve blood glucose management for diabetes and pre-diabetes patients. With rising demand for user-friendly solutions, their current invasive methods were becoming a barrier to user comfort and compliance.
Although the team was aware of various non-invasive technologies, they faced challenges in identifying reliable and accurate solutions that could continuously monitor glucose levels without disrupting daily life. This pushed them to explore emerging innovations that balance continuous monitoring with ease of use.
To strategically position the company in this expanding market, management needed a deeper understanding of recent advancements in non-invasive CGM, including research breakthroughs, regulatory developments, and shifts in consumer preferences. Additionally, they sought crucial insights such as:
- Recent patents and innovations addressing key technical challenges
- New product launches and upcoming technologies
- Collaborations, partnerships, and funding activities among competitors
IP-Based Multi-Parametric Analysis to Identify Key Non-Invasive CGM Innovations
The team was equipped with a clear strategy for navigating the non-invasive CGM market by leveraging insights gained from analyzing IP trends, competitor activity, and product forecasts. They identified that Roche’s focus remained on traditional glucose monitoring, with a decline in patent filings, while Samsung was actively expanding its patent portfolio in non-invasive diabetes solutions.
This comprehensive approach allowed them to make data-backed recommendations to their management team, ensuring they were well-positioned in the growing CGM market. With a deeper understanding of competitor strategies and emerging innovations, they were able to stay competitive and align their efforts with the latest technological advancements in diabetes management.
Key Findings from the Analysis
The analysis of non-invasive CGM innovations revealed multiple key players shaping the market, these included:
Roche
Historically known for glucose diagnostics using test strips and glucometers, Roche has seen a decline in patent activity in recent years. However, recent partnerships with Ellerca Health and Diabeloop signal a shift toward integrated diabetes management ecosystems, including insulin delivery. This strategic pivot indicates Roche’s move from traditional glucose diagnostics and a growing focus on comprehensive diabetes care solutions, highlighting evolving market opportunities.
Samsung
With around 170 patent families in non-invasive glucose monitoring, Samsung is actively advancing Raman and Near-Infrared (NIR) Spectroscopy. Collaborations with universities and MIT have led to the development of an off-axis Raman spectroscopy system showing promising glucose measurement accuracy. Samsung is exploring NIR techniques and may integrate glucose monitoring into future Galaxy Watch models or collaborate with medical device companies like Medtronic, underscoring their commitment to non-invasive diabetes solutions.
Research Process- How did GreyB Help?
Identifying Non-Invasive CGM Technologies
We explored various non-invasive CGM technologies, analyzing patents, scientific papers, and company reports. Using a multi-tiered keyword strategy, we identified over 100 solutions, including Raman Spectroscopy and NIR techniques.
Evaluation and Analysis
Our evaluation focused on technological readiness, market potential, and regulatory challenges. Key players like Samsung, with its promising off-axis Raman Spectroscopy, stood out for potential integration into consumer devices. We also tracked competitors’ patent activity and partnerships, providing insights into market positioning.
Structured Framework and Recommendations
The findings were categorized into three tiers: Tier 1 for immediate action, Tier 2 for mid-term opportunities, and Tier 3 for long-term research. Each recommendation was supported by market readiness analysis, regulatory compliance, and strengths. For instance, while Roche moves towards integrated diabetes ecosystems, Samsung’s innovations position them for future dominance in non-invasive glucose monitoring.
Navigating the complexities of cost, efficiency, and quality in diabetes management requires a strategic approach to emerging non-invasive technologies. Healthcare companies often face challenges such as:
- Managing operational costs while ensuring accessibility for patients.
- Exploring innovative solutions like non-invasive CGM technologies to remain competitive.
- Identifying collaboration opportunities to enhance product effectiveness and patient care.
If you’re interested in addressing these challenges with customized non-invasive CGM solutions and need expert guidance, fill out the form below to connect with our specialists today.
